Saturday 17 October 2026
Export TRIB’s income statement to Excel — free account
Trinity Biotech PLC
TRIB Healthcare Medical Devices
Trinity Biotech PLC’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, down 28.9% from fiscal 2024. In the quarter to March 2026, revenue grew 43.3%, EPS grew 52.1%, free cash flow grew 75.2% and total debt rose 29.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
8.03
0.10
+1.26%
Follow TRIB
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.24 | 0.40 | 0.33 | 0.22 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.09) | 140.45 | (9.94) | (8.79) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.48 | 2.77 | 3.31 | 3.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(25.18) | (122.17) | (24.41) | (34.53) | |
EV/FCF |
(7.57) | (12.05) | (10.28) | (11.77) | |
Quick Ratio |
0.39 | 0.46 | 0.12 | 0.09 | |
Current Ratio |
1.05 | 1.03 | 0.25 | 0.22 | |
Net Debt/EBITDA |
(37.52) | (970.26) | (30.59) | (69.19) | |
Debt/Assets |
110.46% | 110.75% | 128.55% | 134.49% | |
Debt/Equity |
(2.22) | (2.10) | (1.88) | (1.81) | |
Asset Turnover |
0.51 | 0.48 | 0.42 | 0.47 | |
Operating CF/Net income |
0.29 | (0.03) | 0.08 | 0.26 | |
Capex/Depreciation |
(5.92) | (2.23) | (1.10) | (0.06) | |
Interest Coverage |
(1.67) | (0.18) | (0.39) | (1.51) | |
Research and Development Expense of Revenue |
5.88% | 5.71% | 9.56% | 8.47% | |
Selling, General and Administrative Expense of Revenue |
69.48% | 45.12% | 69.26% | 51.48% | |
Intangible Assets out of Total Assets |
0.56 | 0.56 | 0.54 | 0.58 | |
Share Based Compensation of Revenue |
0.87% | 0.44% | 0.33% | 0.15% | |
Graham Net Nets |
(9.60) | (6.34) | (9.63) | (14.31) | |
Graham Number |
370.20 | 374.78 | 394.57 | 374.50 | |
Earnings Yield |
(391.18%) | (227.16%) | (250.90%) | (320.72%) | |
Free Cash Flow Yield |
(133.68%) | (57.70%) | (96.02%) | (120.70%) | |
Revenue per Share |
17.46 | 23.04 | 17.90 | 17.18 | |
Operating CF per Share |
(2.75) | 0.22 | (2.38) | (1.84) | |
Capex per Share |
(6.27) | (2.37) | (1.30) | (0.07) | |
Free Cash Flow per Share |
(9.02) | (2.15) | (3.68) | (1.91) | |
Cash per Share |
2.49 | 2.16 | 8.31 | 3.20 | |
Shareholders Equity per Share |
(79.85) | (88.08) | (116.36) | (119.97) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(79.85) | (88.08) | (116.36) | (119.97) | |
Free Cash Flow |
(5.60) | (1.33) | (2.28) | (1.20) | |
Working Capital |
1.48 | 1.02 | (105.31) | (112.32) | |
Capital Expenditures |
(3.89) | (1.47) | (0.80) | (0.04) | |
Net Current Asset Value |
(116.17) | (122.91) | (141.24) | (146.28) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.36 | 0.10 | 0.07 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.18 | 17.85 | 13.77 | 10.56 | |
Average Payables |
24.78 | 27.83 | 28.24 | 27.57 | |
Average Inventory |
21.54 | 20.48 | 19.10 | 19.27 | |
Average Assets |
96.99 | 100.58 | 104.23 | 100.85 | |
Average Common Equity |
(39.47) | (40.53) | (53.58) | (59.68) |
Columns are period end dates